Literature DB >> 10469846

Forward genetics in mammalian cells: functional approaches to gene discovery.

G R Stark1, A V Gudkov.   

Abstract

Definitive proof of function in biological systems requires genetic analysis. Only when the loss of a particular protein corresponds to the loss of a specific function can one be sure that the protein truly affects the function. Changing the pattern of gene expression through random mutagenesis or by introducing expression libraries, followed by selection of mutant or variant cells and identification of a missing or overexpressed protein, has the power to reveal or confirm the roles of specific components of signaling pathways and to provide mutant cell lines and cDNA reagents to be used in defining detailed mechanisms through structure-function analyses. These examples of forward genetics contrast with reverse genetic approaches, where the function of a known gene product is explored by knockout or replacement. Here we review a broad range of techniques that have been used to alter gene expression randomly in mammalian cells, with examples of specific discoveries that have resulted from these applications of forward genetics.

Entities:  

Mesh:

Year:  1999        PMID: 10469846     DOI: 10.1093/hmg/8.10.1925

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  Genetic analysis of CD28 signaling.

Authors:  Tiffani A Greene; Virginia Smith Shapiro
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Genomewide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells.

Authors:  Moshe Pritsker; Nicole R Ford; Harry T Jenq; Ihor R Lemischka
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-18       Impact factor: 11.205

3.  Identification of RNA-binding proteins that regulate FGFR2 splicing through the use of sensitive and specific dual color fluorescence minigene assays.

Authors:  Emily A Newman; Stephanie J Muh; Ruben H Hovhannisyan; Claude C Warzecha; Richard B Jones; Wallace L McKeehan; Russ P Carstens
Journal:  RNA       Date:  2006-04-07       Impact factor: 4.942

4.  Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5).

Authors:  Mirna Mourtada-Maarabouni; Anwar M Hasan; Farzin Farzaneh; Gwyn T Williams
Journal:  Mol Pharmacol       Date:  2010-04-26       Impact factor: 4.436

5.  Act1, an NF-kappa B-activating protein.

Authors:  X Li; M Commane; H Nie; X Hua; M Chatterjee-Kishore; D Wald; M Haag; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

6.  Mutagenesis by reversible promoter insertion to study the activation of NF-kappaB.

Authors:  Eugene S Kandel; Tao Lu; Youzhong Wan; Mukesh K Agarwal; Mark W Jackson; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

Review 7.  Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.

Authors:  Daniel J Cooper; Giulia Zunino; John L Bixby; Vance P Lemmon
Journal:  Mol Cell Neurosci       Date:  2016-07-18       Impact factor: 4.314

8.  Selection-subtraction approach (SSA): a universal genetic screening technique that enables negative selection.

Authors:  Aatur D Singhi; Roman V Kondratov; Nickolay Neznanov; Mikhail V Chernov; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-08       Impact factor: 11.205

Review 9.  How cells respond to interferons revisited: from early history to current complexity.

Authors:  George R Stark
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-01       Impact factor: 7.638

10.  Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB.

Authors:  Tao Lu; Mark W Jackson; Aatur D Singhi; Eugene S Kandel; Maojing Yang; Yi Zhang; Andrei V Gudkov; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.